We’re pleased to announce that our newest clinical NGS variant interpretation and reporting solution is now available in Europe.
What is QCI Interpret One?
QCI Interpret One is clinical decision support software integrated with professional variant interpretation services that enables rapid, evidence-based reporting of oncology NGS tests at scale.
Connected to the world’s most comprehensive, manually curated knowledge base that is updated weekly, QCI Interpret One dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with full transparency.
Users get access to over 200,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapies and regional clinical trials, based on the lab’s regional labels and guidelines.
For US users, QCI Interpret One generates reports according to FDA/NCCN/WHO guidelines for therapeutic, prognostic, and diagnostic actionability. View Sample Report.
For EMEA users, QCI Interpret One generates reports according to EMA/ESMO/ELN/WHO guidelines for therapeutic, prognostic, and diagnostic actionability. View Sample Report.
Live Webinar: October 15 at 10 AM EST | 4 PM CET
Rapid, evidence-based reporting for NGS oncology tests at scale
Learn more about QCI Interpret One in our upcoming live webinar, Thursday, October 15 at 10 AM EST | 4 PM CET. Our experts will provide an overview of the solution, as well as demonstrate how QCI Interpret One can help clinical laboratories grow caseload volume, accelerate test turnaround time, and deliver oncologist-ready reports without requiring additional staff.